Telitacicept 160mg

DRUG5 trials

Conditions

Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)IgA NephropathyIgA Nephropathy (IgAN)Proliferative Glomerulonephritis With Monoclonal Immunoglobulin DepositsSystemic Lupus Erythematosus (SLE)

Phase 1

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Active, not recruitingNCT06656962

Renmin Hospital of Wuhan UniversityAntineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)

Start: 2024-10-10End: 2026-10-30Updated: 2024-10-24

Phase 2

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

TerminatedNCT04905212

RemeGen Co., Ltd.IgA Nephropathy

Start: 2021-11-04End: 2023-11-09Updated: 2023-12-06

Telitacicept for PGNMID: A Single-Arm Study

Active, not recruitingNCT07111338

Peking University First HospitalProliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

Start: 2025-07-12End: 2027-05-29Target: 10Updated: 2025-08-08

Phase 3

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Active, not recruitingNCT07098897

The Affiliated Hospital of Xuzhou Medical UniversityIgA Nephropathy (IgAN)

Start: 2024-08-01End: 2025-09-30Updated: 2025-08-01

Phase 4

Immune Cell Subsets in SLE Patients Treated with Telitacicept

Active, not recruitingNCT06677801

Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySystemic Lupus Erythematosus (SLE)

Start: 2024-10-11End: 2027-10-31Target: 50Updated: 2024-11-07

Related Papers

Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study

CNS Neuroscience & Therapeutics2022-07-1831 citations